MRC awards $11.3M to researchers using AstraZeneca compounds

The U.K.'s Medical Research Council (MRC) awarded L7 million ($11.3 million) in funding for 15 research projects to evaluate compounds provided by AstraZeneca plc (LSE:AZN; NYSE:AZN). MRC said the disease areas include Alzheimer's disease, cancer, lung disease, motor neuron disease and muscular dystrophies. Eight of the projects will involve clinical trials with the compounds, while seven projects will focus on preclinical work. MRC could not be reached for additional details on the projects. ...